(CA)
TIFCEMALIMAB(INNE)
TIFCÉMALIMAB(INNF)
TIFCEMALIMAB(INNS)
TIFCEMALIMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS BTLA (B AND T LYMPHOCYTE ASSOCIATED, BTLA1, CD272)], CHIMERIC MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN CHIMERIC (1-446) [VH (MUS MUSCULUS IGHV14-3*02 (82.3%) -IGHJ3*01 (91.7%)/HOMO SAPIENS IGHV1-3*01 (77.1%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (120-217), HINGE 1-12 S10>P (227) (218-229), CH2 (230-339), CH3 (340-444), CHS (445- 446)) (120-446)], (133-219')-DISULFIDE WITH KAPPA LIGHT CHAIN CHIMERIC (1'-219') [V-KAPPA (MUS MUSCULUS IGKV1-135*01 (92%) -IGKJ2*03 (91.7%)/HOMO SAPIENS IGKV2-30*01 (87.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-47.55-57.94-102) (1'-112') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (158), V101 (196) (113'-219')]; DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA. PROPOSED INN: LIST 122, PROPOSED LIST: 124, RECOMMENDED INN: LIST 86(WHO)
TIFCEMALIMABUM(INN)